Search for: "Aurobindo Pharma Ltd" Results 1 - 20 of 34
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
17 Mar 2020, 1:32 pm by Noble McIntyre
Lidocaine HCl Topical Solution 4%, 50ml, has been recalled by Teligent Pharma, Inc. due to super potency. [read post]
21 Sep 2014, 9:01 pm by Patent Docs
Aurobindo Pharma Ltd. et al. 1:14-cv-01203; filed September 17, 2014 in the District Court of Delaware • Plaintiff: Reckitt Benckiser LLC • Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc. [read post]
26 May 2014, 9:59 pm by Patent Docs
• Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA, Inc.; Aurolife Pharma LLC Infringement of U.S. [read post]
17 Mar 2014, 9:59 pm by Patent Docs
Ltd.; Aurobindo Pharma Limited; Aurobindo Pharma USA Inc.; Dr. [read post]
23 Feb 2014, 9:29 pm by Patent Docs
Aurobindo Pharma Ltd. et al. 1:14-cv-00215; filed February 19, 2014 in the District Court of Delaware • Plaintiffs: AbbVie Inc.; Wisconsin Alumni Research Foundation • Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc. [read post]
8 Dec 2013, 8:02 pm by Patent Docs
• Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc. [read post]
3 Aug 2013, 6:35 am by Anubha Sinha
Other significant suppliers are Ranbaxy Labs, Hetero Labs, Aurobindo Pharma, Haffkine Bio-Pharmaceutical Corporation, Biological E and Micro Labs Pharma. [read post]
3 Mar 2013, 12:06 pm by Rajiv Kr. Choudhry
Granted P S Rao 547/CHE/2006 AUROBINDO PHARMA LIMITED Refused P. [read post]
27 Jan 2013, 8:57 pm by Patent Docs
• Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc. [read post]
12 Oct 2011, 3:46 am by Marie Louise
  Highlights this week included: Indian generics Aurobindo Pharma Limited and MedChem join Medicines Patent Pool (Spicy IP) (IP Watch) (IPBiz)   Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored. [read post]
1 Aug 2011, 8:19 am
., Aurobindo Pharma Ltd., and Teva Pharmaceuticals, had filed an Abbreviated New Drug Application (ANDA) seeking to utilize Lilly's patented formula and claiming invalidity of Lilly's patent, No. 5,658,590, Treatment of attention-deficit/hyperactivity disorder, which has been issued by the US Patent Office. [read post]